Overview

* AirSculpt ( AIRS ) Q2 revenue declines 13.7%, missing analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 beats analyst estimates, indicating operational efficiency

* Co announces CFO Dennis Dean's retirement, pending successor appointment

Outlook

* Company affirms 2025 revenue guidance of $160 mln to $170 mln

* AirSculpt ( AIRS ) expects 2025 adjusted EBITDA of $16 mln to $18 mln

* Company confident in accelerating sales improvement through new offerings

* AirSculpt ( AIRS ) sees growth strategy enhancing comparable sales improvement

Result Drivers

* NEW OFFERINGS - Co piloted skin tightening and expanded financing options to attract more customers

* DEBT REDUCTION - Co reduced debt by $16 mln, strengthening its balance sheet

* LEAD GROWTH - Record growth in leads and increased consultations indicate rising consumer interest

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $44 mln $45.40

Revenue mln (4

Analysts

)

Q2 Net -$600,00

Income 0

Q2 Beat $5.80 $5.33

Adjusted mln mln (4

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy."

* Wall Street's median 12-month price target for AirSculpt Technologies Inc ( AIRS ) is $4.75, about 39.2% below its July 31 closing price of $6.61

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)